Lipidor and Cadila Pharmaceuticals announce agreement on Phase III Clinical Study and joint commercialization of topical Psoriasis product
Lipidor AB and Cadila Pharmaceuticals Limited, one of the largest pharmaceutical manufacturing groups in India, have entered into a collaboration agreement on the commercialization of a sprayable anti-psoriatic product consisting of the generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO®. The product targets patients with mild to moderate psoriasis. Under the collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.
“We are very pleased with our collaboration with Cadila Pharmaceuticals, which will enable us to bring this important psoriasis product to the market”, said Dr. Anders Carlsson, CEO of Lipidor AB.
“Cadila Pharmaceuticals’ partnership with Lipidor AB evolves from its vision to partner with leading global research institutions to find novel, innovative and affordable solutions for unmet medical needs. Psoriasis is a condition with high prevalence in India and globally”, said Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd., India.
According to recent estimates psoriasis affects 2-3% of the world’s population. Psoriasis Vulgaris is a long lasting (chronic) autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors. Quality of life aspects, including self-consciousness and social withdrawal are important factors in the management of the disease including treatment compliance. Various kinds of topical ointments, creams and lotions are commonly prescribed treatments for psoriasis, but they show low compliance rates, largely due to their greasiness and inability to absorb into the skin wherefore they are present on the skin for a long time after application.
About Lipidor AB (www.lipidor.se)
Lipidor AB is a Swedish, privately held lipid technology company focusing on dermatology and skin care. Its novel proprietary AKVANO® formulation technology is a unique lipid solution with the ability to incorporate and deliver active ingredients in product areas such as reformulation of existing topical products, formulation of NCEs, and also products for innovative skin and wound care.
About Cadila Pharmaceuticals Ltd (www.cadilapharma.com )
Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat, India. Over the last six decades, it has been developing and manufacturing pharmaceutical products in over 45 therapeutic areas and selling and distributing these in
over 100 countries around the world. It employs more than 7 000 employees. Cadila Pharmaceuticals was the first Indian company to get IND approvals by USFDA for clinical trials to be conducted in India.
For further information, please contact:
Dr. Anders Carlsson, +46 (0)73 778 0643
CEO, Lipidor AB
Dr. Manjul Joshipura, +91 - 2718 - 225001-15 (Ext. 857)
Vice President, Medical Services, Cadila Pharmaceuticals Ltd.